Edwards Lifesciences Corporation $EW Shares Sold by Epoch Investment Partners Inc.

Epoch Investment Partners Inc. decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 8.2% in the 1st quarter, HoldingsChannel reports. The firm owned 202,706 shares of the medical research company’s stock after selling 18,078 shares during the period. Epoch Investment Partners Inc.’s holdings in Edwards Lifesciences were worth $16,233,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after acquiring an additional 4,108,270 shares during the last quarter. Viking Global Investors LP acquired a new position in Edwards Lifesciences during the third quarter worth approximately $238,688,000. Marshall Wace LLP increased its holdings in shares of Edwards Lifesciences by 66.1% during the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after buying an additional 2,359,128 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Edwards Lifesciences by 341.1% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,890,859 shares of the medical research company’s stock worth $151,420,000 after buying an additional 1,462,238 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

EW stock opened at $82.67 on Friday. The firm has a market cap of $47.60 billion, a P/E ratio of 47.51, a price-to-earnings-growth ratio of 2.07 and a beta of 0.86. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29. The stock has a 50-day simple moving average of $87.73 and a 200-day simple moving average of $83.88.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.Edwards Lifesciences’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 45,577 shares of company stock valued at $3,855,527. Corporate insiders own 0.31% of the company’s stock.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards Lifesciences beat Q2 estimates on both earnings and revenue, with sales rising 13.6% year over year to $1.74 billion, helped by strong demand for heart-valve products and growing adoption of mitral and tricuspid therapies.
• Positive Sentiment: The company raised the low end of its full-year revenue outlook to $6.6 billion-$6.9 billion and also lifted its TAVR growth guidance, signaling management confidence in continued momentum.
• Positive Sentiment: Analysts turned more constructive after the report: JPMorgan raised its price target to $105 and kept an overweight rating, while Leerink upgraded the stock to outperform with a $101 target.
• Positive Sentiment: Commentary from Wall Street framed the quarter as evidence that Edwards remains a top medtech growth story, with its core TAVR franchise and newer structural heart therapies driving the upside.
• Neutral Sentiment: The company’s updated Q3 and full-year EPS guidance was broadly in line with expectations, suggesting the current move is being driven more by sales strength and sentiment than by a major earnings surprise.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on EW shares. Evercore reissued an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Barclays reaffirmed an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Truist Financial boosted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $101.00 price target on the stock in a report on Friday. Finally, Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $99.55.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.